Ormhoj, Maria and Abken, Hinrich and Hadrup, Sine R. (2022) Engineering T-cells with chimeric antigen receptors to combat hematological cancers: an update on clinical trials. CANCER IMMUNOLOGY IMMUNOTHERAPY, 71 (10). pp. 2301-2311. ISSN 0340-7004, 1432-0851
Full text not available from this repository. (Request a copy)Abstract
Chimeric antigen receptor (CAR) redirected T-cells has shown efficacy in the treatment of B-cell leukemia/lymphoma, however, high numbers of relapses occur due to loss of targeted antigen or intrinsic failure of the CAR T-cells. In this situation modifications of the basic strategy are envisaged to reduce the risk of relapse, some of them are in early clinical exploration. These include simultaneous targeting of multiple antigens or combination of CAR T-cell therapy with other treatment modalities such as checkpoint inhibitors. The review evaluates and discusses these modified advanced therapies and pre-clinical approaches with respect to their potential to control leukemia and lymphoma in the long-term.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | LYMPHOMA; THERAPY; CD19; REMISSION; RESPONSES; EFFICACY; DESIGN; TARGET; BCMA; Chimeric antigen receptor; Hematological cancer; Clinical trial |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Immunologie |
| Depositing User: | Petra Gürster |
| Date Deposited: | 09 Jan 2025 10:57 |
| Last Modified: | 09 Jan 2025 10:57 |
| URI: | https://pred.uni-regensburg.de/id/eprint/57247 |
Actions (login required)
 |
View Item |
